Protalix Biotherapeutics, Inc. (PLX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Protalix Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases, utilizing its proprietary ProCellEx plant cell-based protein expression system. The company's primary commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). Operations are primarily conducted in Israel, which is currently facing regional military conflicts; however, the company designates its facilities as an "essential enterprise" and reports no material adverse impact on operations to date.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Total Revenue | $53,646 | $25,771 | $19,896 |
| Net Income (Loss) | $22,094 | $(3,455) | $3,777 |
| Operating Income | $25,818 | $(2,973) | $4,672 |
| Operating Margin | 48.1% | -11.5% | 23.5% |
| Cash and Cash Equivalents | $27,420 | $17,895 (End of Period 2025) | N/A |
| Short-term Bank Deposits | $13,236 | $15,593 | N/A |
| Total Liquidity | $40,656 | $33,488 | N/A |
| Net Cash Provided by Operating Activities | $11,625 | $(10,291) | N/A |
| Debt | None reported | None reported | N/A |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue for the six months ended June 30, 2026, increased 108% to $53.6 million compared to $25.8 million in the prior year period. This was driven primarily by a $25.0 million milestone payment from partner Chiesi Farmaceutici S.p.A. following the EU approval of a new dosing regimen (2 mg/kg every-four-weeks) for Elfabrio in March 2026.
- Profitability Turnaround: The company reported a net income of $22.1 million for the six-month period, a significant improvement from a net loss of $3.5 million in the same period in 2025.
- Product Sales: Revenues from selling goods increased 7% year-over-year to $27.2 million. Sales to Chiesi increased significantly ($17.5M vs $9.8M), while sales to Pfizer decreased ($5.7M vs $12.6M) due to Pfizer's inventory management and prior manufacturing issues.
- R&D Expenses: Net R&D expenses remained relatively flat at $9.8 million, despite an increase in gross expenses, due to a $2.1 million reduction recorded from a new Israeli R&D grant.
- Balance Sheet: Total assets grew to $110.3 million from $82.3 million, largely due to increased cash, accounts receivable, and inventory levels.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash and short-term deposits ($40.7 million) are sufficient to satisfy capital needs for at least 12 months from the filing date.
- Future Funding: The company expects to continue incurring significant R&D expenditures for the RELEASE study and other pipeline candidates. Future funding may be required via equity offerings, debt, or collaborations.
- Regulatory & Commercial Milestones: The company remains eligible for up to $270 million in additional milestones from Chiesi (Ex-US) and $740 million (US) based on regulatory and commercial performance.
- Key Risks:
- Geopolitical Instability: Ongoing military conflicts in the Middle East (Israel, Iran, Gaza, Lebanon) pose risks to operations, supply chains, and regulatory authorities, though the company has mitigated risks by storing drug substance in multiple locations.
- Tariffs: New U.S. tariffs on pharmaceutical products announced in April 2026, effective September 2026, could materially impact commercialization in the U.S.
- Partner Dependence: Revenue is heavily reliant on Chiesi and Pfizer; ordering patterns may not reflect actual patient demand due to inventory stocking behaviors.
- Grant Uncertainty: While the company intends to file for grants under the new Israeli R&D Law, there is no guarantee of approval or full funding amounts.
Investor Verification Checklist
- Verify the sustainability of the $25.0 million Chiesi milestone revenue and the timing of future potential milestones.
- Monitor the impact of the new U.S. tariffs (effective Sept 2026) on the cost structure and pricing of Elelyso and Elfabrio in the U.S. market.
- Assess the operational continuity of the Israeli manufacturing facility amidst ongoing regional military conflicts.
- Review the status of the RELEASE study and other pipeline candidates (PRX-115, PRX-119) to gauge future R&D burn rate.
- Confirm the collection of the $14.9 million in subsequent sales to Chiesi and $1.5 million to Pfizer noted in the subsequent events section.